Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 12
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Closed
24 to 45
Pharmaceutical / Industry
2004_013
NCT00090220
2.
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Prevention
Completed
11 to 17
Pharmaceutical / Industry
2005_092
V501-025, NCT00325130
3.
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Completed
11 to 17
Pharmaceutical / Industry
2005_093
V501-024, NCT00337428
4.
Immunogenicity of GSK Bio's HPV Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Completed
18 to 45
Pharmaceutical / Industry
108933
NCT00423046
5.
Safety, Tolerability and Immunogenicity of Quadrivalent Human Papillomavirus (HPV) Vaccine in Healthy Females 9 to 15 Years of Age in India
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Completed
9 to 15
Pharmaceutical / Industry
2006_038
V501-029, NCT00380367
6.
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Closed
9 to 26
Pharmaceutical / Industry
2007_021
V501-030, NCT00496626
7.
A Controlled Trial to Assess the Immunogenicity of a Proposed Paediatric Dosing Schedule of Human Papillomavirus Vaccine
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Biomarker/Laboratory analysis, Prevention
Completed
9 to 26
Other
H07-00928
BCGov-01, NCT00501137
8.
Broad Spectrum HPV Vaccine Dose Ranging Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Prevention
Completed
16 to 23
Pharmaceutical / Industry
2005_086
V502-001, NCT00260039
9.
V501 (Gardasil) Study in Preadolescent Females
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Prevention
Closed
9 to 17
Pharmaceutical / Industry
2006_052
V501-028, NCT00411749
10.
Broad Spectrum HPV (Human Papillomavirus) Vaccine (V505) in 16 to 26 Year Old Women
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Prevention
Closed
16 to 26
Pharmaceutical / Industry
2007_567
V505-001, NCT00520598
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute